Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials
Gennova gears up to launch mRNA vaccine for Covid

India’s first indigenous mRNA vaccine candidate has received approval from Indian Drug regulators to initiate Phase I/II human clinical trial. The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of M/o Science & Technology.

The mRNA vaccines do not use the conventional model to produce immune response. Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus. The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease. mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria. Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.

Gennova, in collaboration with HDT Biotech Corporation, Seattle, USA, has worked together to develop an mRNA vaccine candidate. HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activity in animals. The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.

Gennova’s vaccine candidate uses the most prominent mutant of spike protein (D614G) and also uses the self-amplifying mRNA platform, which gives the advantage of a low dosing regimen compared with the non-replicating mRNA or traditional vaccines. HGCO19 uses the adsorption chemistry so that the mRNA is attached on the surface of the nano-lipid carrier to enhance the release kinetics of the mRNA within the cells compared to the encapsulation chemistry.

HGCO19 is stable at 2-8°C for two months. Gennova has completed all preliminary work and should be initiating the Phase I/II Human clinical trial soon since the approval from the DCGI office has been received.

The Department of Biotechnology, Ministry of Science & Technology, Government of India is implementing the IndCEPImission ‘India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development’ which is aligned with the Global Initiative of CEPIand aims to strengthen the development of vaccines and associated competencies/technologies for the diseases of epidemic potential in India. The Ind-CEPI mission of DBT is implemented by its PSU, Biotechnology Industry Research Assistance Council ( BIRAC).

‘Establishment of a suchindigenous technology platform will not only empower India to handle the COVID-19 pandemic but also ensure the preparedness for future outbreaks’ said Dr Renu GennovaSwarup, Secretary, Department of Biotechnology and Chairperson BIRAC.

Tags : #mRNAVaccine #Gennova #BIRAC #DeapartmentofBiotechnology #HGCO19 #HDTBiotechCorporation

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025
Sarvodaya Hospital, Greater Noida West, Launches Next-Gen Fully Active Robotic System for Joint ReplacementJuly 10, 2025
Children Dazzle the Stage at Faridabad Talent Hunt at Asian Institute of Medical SciencesJuly 10, 2025
From Macro to Mandate: How India's Affluent Investors are Positioning for Global ShiftsJuly 10, 2025
Actress-turned-Entrepreneur raises alarm over hidden pet health crisis in IndiaJuly 10, 2025
Aster CMI Performs Complex Tracheal Resection and Anastomosis to Cure Chronic BreathlessnessJuly 10, 2025
CARE Hospitals, Hitech City introduces India’s Most Advanced AI-Powered Robotic Surgery SystemJuly 09, 2025
Nestlé India Supports Flood Relief Efforts in Himachal PradeshJuly 09, 2025
When Machines Whisper Care: The Quiet Rise of Medical Bots in Elderly WardsJuly 09, 2025
Integrating mental health into India’s primary healthcare, what’s next?July 09, 2025
Where the Mind Finds Rest: How Green Spaces Quiet the City NoiseJuly 09, 2025
Can a Smartphone Heal Your Wound?July 09, 2025
University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025